Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live00:18

Revolution Medicines (RVMD) should post "strong launch numbers" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.

The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.

Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.

The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.

UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.

UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.

Price: 206.08, Change: -15.07, Percent Change: -6.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2663975310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-29 00:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663975310","market":"sh","top_or_hot":-1,"title":"Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) should post \"strong launch numbers\" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.</p><p>The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.</p><p>Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.</p><p>The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.</p><p>UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.</p><p>UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.</p><p>Price: 206.08, Change: -15.07, Percent Change: -6.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-29 00:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) should post \"strong launch numbers\" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.</p><p>The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.</p><p>Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.</p><p>The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.</p><p>UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.</p><p>UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.</p><p>Price: 206.08, Change: -15.07, Percent Change: -6.81</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663975310","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663975310","pubTimestamp":1787933923,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Revolution Medicines  should post \"strong launch numbers\" for pancreatic cancer drug Rasonque , which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raise","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","CANC":"TEMA ONCOLOGY ETF","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BBH":"VanEck Biotech ETF","RVMD":"Revolution Medicines, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"瑞银表示，Revolution Medicines 将推出 Rasonque 的“强劲上市”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.5,"IDNA":0.6,"PTH":0.6,"BBH":0.6,"CANC":0.6},"content_text":"Revolution Medicines (RVMD) should post \"strong launch numbers\" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.Price: 206.08, Change: -15.07, Percent Change: -6.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663975310","isCrawlerRequest":true}